Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Pioglitazone & bladder cancer – what’s the story?

September 18th 2011

On June 9th, France suspended new prescriptions of pioglitazone due to concerns over an increased risk of bladder cancer. Within hours the Germans followed suit….

In early studies of pioglitazone (a PPAR alpha agonist), there were observations of transitional cell neoplasia in the bladders of male rats (but not in females nor in mouse models). Subsequently the clinical development of ragaglitazar, a dual PPAR agonist, was halted due to bladder tumours in rats and in one mouse.

This prompted the FDA to request a study to assess bladder cancer risk over a 10-year exposure and this is being undertaken using the Kaiser Permanente North Carolina (KPNC) registry. It also led to scrutiny of PROactive, a study of secondary cardiovascular prevention in type 2 diabetes, using pioglitazone.

In PROactive, there were 14 cases of bladder tumour in the pioglitazone group versus 6 with placebo. After independent assessment, the numbers fell to six and three, a non-significant difference. In a 5-year (interim) analysis of the KPNC, there was no increase in bladder cancer with pioglitazone use unless duration of exposure (>2years) was taken into account (when a statistically significant increase was shown). The full 10-year data are awaited, as are follow-on data from PROactive. The French dataset (CNAMTS study) has not been published.

These ‘imbalances’ seen with bladder cancer risk need to be taken into context of no overall increase in malignancy (indeed, ‘protection’ from some cancers such as breast and kidney) and significant benefits, such as a 50% reduction in secondary prevention of stroke.

The European Medicines Agency has taken the view that Pioglitazone should continue to be available for use, but be avoided in patients with bladder cancer or haematuria. Regular review is also recommended but since all patients will be having at least yearly checks of urine albumin creatine ratio (UACR), one could argue that this is already in place…

Professor Steve Bain

Categories: Updates

Diabetes Updates Archive

calendar-iconDiabetes Updates Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

AstraZenecaSanofi DiabetesNovo NordiskNapp Diabetes

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes CareAmgen

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership